Shots:
- The EC has approved Zynyz (retifanlimab) + Pt-based CT for the 1L treatment of adults with metastatic or inoperable locally recurrent SCAC
- Approval was based on P-III (POD1UM-303/InterAACT2) trial assessing Zynyz + carboplatin & paclitaxelvs PBO & CT in treatment-naïve SCAC pts
- The trial showed a 37% reduction in the risk of progression or death (mPFS: 9.3 vs 7.4mos.), with improvement observed across all 2EPs, incl. key 2EP of OS; data was published in The Lancet
Ref: Incyte | Image: Incyte | Press Release
Related News: Incyte Reports the Topline P-III (frontMIND) Trial Data on Monjuvi (Tafasitamab) Combination for Diffuse Large B-Cell Lymphoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
